Literature DB >> 29797035

Pharmacokinetics of imipenem in plasma and cerebrospinal fluid in patients with intracerebral hemorrhage.

Lingti Kong1, Hongzhou Xu2, Chenchen Wu3, Xuguang Zhao4, Xiaofei Wu5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29797035     DOI： 10.1007/s00228-018-2488-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Nosocomial Infections and Outcomes after Intracerebral Hemorrhage: A Population-Based Study.

Authors:  Santosh B Murthy; Yogesh Moradiya; Jharna Shah; Alexander E Merkler; Halinder S Mangat; Costantino Iadacola; Daniel F Hanley; Hooman Kamel; Wendy C Ziai
Journal:  Neurocrit Care       Date:  2016-10       Impact factor: 3.210

4.  Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.

Authors:  C Verwaest
Journal:  Clin Microbiol Infect       Date:  2000-06       Impact factor: 8.067

Review 5.  The use of carbapenems in the treatment of serious infections.

Authors:  Robert P Baughman
Journal:  J Intensive Care Med       Date:  2009-07-17       Impact factor: 3.510

6.  Vancomycin Pharmacokinetic Parameters in Patients with Hemorrhagic Stroke.

Authors:  Kathryn A Morbitzer; J Dedrick Jordan; Kelly A Sullivan; Emily A Durr; Casey M Olm-Shipman; Denise H Rhoney
Journal:  Neurocrit Care       Date:  2016-10       Impact factor: 3.210

Review 7.  Safety of imipenem/cilastatin in neurocritical care patients.

Authors:  Jason Hoffman; Jason Trimble; Gretchen M Brophy
Journal:  Neurocrit Care       Date:  2008-12-31       Impact factor: 3.210

8.  Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections.

Authors:  R F Jacobs; G L Kearns; A L Brown; D C Longee
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

9.  Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.

Authors:  Lingti Kong; Yan Tang; Xiaohua Zhang; Guoyu Lu; Meiling Yu; Qingping Shi; Xiaofei Wu
Journal:  Ann Pharmacother       Date:  2017-07-05       Impact factor: 3.154

10.  Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.

Authors:  Christoph P Hornik; Amy H Herring; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; John van den Anker; Michael Cohen-Wolkowiez; Reese H Clark; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 3.806
View more
  1 in total

1.  Imipenem Population Pharmacokinetics: Therapeutic Drug Monitoring Data Collected in Critically Ill Patients with or without Extracorporeal Membrane Oxygenation.

Authors:  Wenqian Chen; Dan Zhang; Wenwen Lian; Xiaoxue Wang; Wenwen Du; Zhu Zhang; Dongjie Guo; Xianglin Zhang; Qingyuan Zhan; Pengmei Li
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.